-1768251391415.webp&w=3840&q=75)
2025 MaTOS Lung | Session XIII | Targeted Therapy Forum-Part III Case-Based Panel Discussion
Overview
Dr. Ricciuti presented Case 1, a 56-year-old with KRAS G12C metastatic lung cancer showed limited IO benefit; panel favored chemo-IO and clinical trials for this challenging mutation.
Case 2, presented by Dr. Singhi, is a 55-year-old with metastatic squamous lung cancer and KRAS/STK11 mutations had an exceptional response to immunotherapy alone, prompting discussion of consolidation options.
Dr. Gomez presented Case 3, a 95-year-old with recurrent mucinous lung cancer highlighted treatment choices, tolerance, quality of life, and limits of aggressive therapy in the very elderly.
Case 4, presented by Dr. Kim, reviewed a 74-year-old with PD-L1–negative metastatic squamous lung cancer, high TMB, complex comorbidities, and debated systemic, IO, or surgical options.
Dr. Karim presented Case 5, a 65-year-old with atypical lung carcinoid showed limited adjuvant benefit, later metastasis, octreotide response, evolving classification, and trial-based options.
The wrap up session discussed managing oligo-progression on immunotherapy, favoring local therapy (SABR/surgery), individualized plans, IO continuation or rechallenge, and noting risk of new primaries.
Case 2, presented by Dr. Singhi, is a 55-year-old with metastatic squamous lung cancer and KRAS/STK11 mutations had an exceptional response to immunotherapy alone, prompting discussion of consolidation options.
Dr. Gomez presented Case 3, a 95-year-old with recurrent mucinous lung cancer highlighted treatment choices, tolerance, quality of life, and limits of aggressive therapy in the very elderly.
Case 4, presented by Dr. Kim, reviewed a 74-year-old with PD-L1–negative metastatic squamous lung cancer, high TMB, complex comorbidities, and debated systemic, IO, or surgical options.
Dr. Karim presented Case 5, a 65-year-old with atypical lung carcinoid showed limited adjuvant benefit, later metastasis, octreotide response, evolving classification, and trial-based options.
The wrap up session discussed managing oligo-progression on immunotherapy, favoring local therapy (SABR/surgery), individualized plans, IO continuation or rechallenge, and noting risk of new primaries.
Target Audience
Physicians
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Moderator: Stephen V. Liu, MD
Speakers and Panelists:
Biagio Ricciuti, MD, PhD
Eric K. Singhi, MD
Jorge E. Gomez, MD
Chul Kim, MD, MPH
Nagla Abdel Karim, MD
Panelists:
Megan E. Daly, MD
Fred R. Hirsch, MD, PhD, FASCO
Alberto Chiappori, MD
Misako Nagasaki, MD, PhD
Date of Release
January 9th, 2026
-1769196766441.webp&w=3840&q=75)
-1769196674841.webp&w=3840&q=75)